9 news items
Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
IBRX
17 May 24
and prevalence data, potential benefits to patients, potential treatment actions for patients, the described mechanism of action and results and contributions
ImmunityBio, Serum Institute Of India Agree On An Exclusive Arrangement For Global Supply Of Bacillus Calmette-Guerin Across All Cancer Types
IBRX
2 May 24
to ensure availability of BCG for all approved indications that benefit from ANKTIVA's triangle offense of natural killer cells, T cells, and memory T
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
IBRX
2 May 24
indications that benefit from ANKTIVA's triangle offense of natural killer cells, T cells, and memory T cells
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
IBRX
25 Apr 24
, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
IBRX
22 Apr 24
of the United States, the regulatory review process and timing thereof, market and prevalence data, potential benefits to patients, potential treatment
cwpib049be
ACRS
IBRX
NUVB
14 Mar 24
and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients
d9lsmrh52v8ysan 8v90fy2wd4
IBRX
6 Mar 24
potential benefit to patients, potential additional studies and trials, methods, regulatory pathways, and ImmunityBio's investigational agents as compared
z9tww aqmovpvnve6nz6
IBRX
5 Mar 24
and Medical Officer at ImmunityBio. "These data preliminarily appear to validate what we know about the benefit of enhancing NK cell function and the potential
xchxlbuv341zym2vvamxo5nx6kxxyulsfgdn
IBRX
21 Feb 24
, potential benefit to patients, potential additional studies and trials, methods, regulatory pathways, and ImmunityBio's investigational agents as compared
- Prev
- 1
- Next